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I. INTRODUCTION 
1. Friedreich Ataxia (FA) 
FRDA is a common autosomal recessive 
neurodegenerative disease (1/50,000 live births) 
characterized by a progressive gait and limb ataxia with 
lack of tendon reflexes in the legs, dysarthria and 
pyramidal weakness of the inferior limbs
i
. The term 
"dystaxia" is a rarely used synonym for F.A. 
Hypertrophic Cardiomyopathy is also observed in most 
FRDA patients. The condition is named after 
the German physician NikolausFriedreich, who first 
described it in the 1860s.Friedreich ataxia is an orphan 
disease having Orphanet orphan number ORPHA95. 
FARA (Friedreich Ataxia Research Alliance) is an 
organization dedicated towards the conducting active 
research for the diagnosis and treatment of Friedreich 
ataxia.
1
 
2. Genetic Predisposition of Friedreich Ataxia 
(Epigenetics) 
Mutations in the FXN gene cause Friedreich ataxia. This 
gene provides instructions for making a protein called 
frataxin. One region of the FXN gene contains a 
segment of DNA known as a GAA trinucleotide repeat. 
This segment is made up of a series of three DNA 
building blocks (one guanine and two adenines) that 
                                                 
 
appear multiple times in a row. Normally, this segment 
is repeated 5 to 33 times within the FXN gene.In people 
with Friedreich ataxia, the GAA segment is repeated 66 
to more than 1,000 times. The length of the GAA 
trinucleotide repeat appears to be related to the age at 
which the symptoms of Friedreich ataxia appear. People 
with GAA segments repeated fewer than 300 times tend 
to have a later appearance of symptoms (after age 25) 
than those with larger GAA trinucleotide repeats. The 
abnormally long GAA trinucleotide repeat disrupts the 
production of frataxin, which severely reduces the 
amount of this protein in cells. Certain nerve and 
muscle cells cannot function properly with a shortage of 
frataxin leading to the characteristic signs and 
symptoms of Friedreich ataxia.
ii
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ABSTRACT 
The present report discusses about the clinical trial requirements for Friedreich ataxia disease such as inclusion and exclusion 
criteria for the patients,primary/secondary outcome measuresrequired for assessing the efficacy of therapies viarating scales, 
physical activity tests, biomarkersand number of subjects/patients to be enrolled in each phase of the clinical trials of 
Friedreich ataxia (F.A.). These parameters have been selected from the ongoing and completed clinical trials for F.A. as 
reported in Clinical trials.gov and Friedreich Ataxia Research Alliance (FARA) official website. A total of 33 clinical 
trialdetails werereviewed for compilation of the above mentioned parameters. For the purpose of this report, the most useful 
and most commonly assessedprimary/secondary outcome measureswith respect to efficacy as well as inclusion and exclusion 
criteria have been selected and are being cited in this review.The outcome measures for the purpose of efficacy trials can 
broadly be classified as primary and secondaryoutcome measures and in each category, subclasses are being presented in the 
order of their priority as determined by their usefulness and common occurrence in all trials mentioned. These outcome 
measuresincludeRating Scales for Friedreich Ataxia, Physical Activity Tests and Biomarkers, evaluation of Cardiac 
functionality viz. left ventricular wall mass, non-invasive measures of systolic and diastolic ventricular function, 
echocardiography and immunogenicity.The genetic predisposition of Friedreich ataxia (epigenetics) leading to the 
pathogenesis of the disease is also discussed in this report. Based on above primary and secondary outcomes measures and 
inclusion and exclusion criteria, a tabular representation of the ongoing/ completed clinical trials representing the efficacy 
studies of the test molecules and the patient involvements in each clinical trial is also been listed. Various aspects of clinical 
trialsneeded for assessing ataxic stage in Friedreich ataxia disease is been reviewed in this article. 
Key words:Friedreich ataxia, Friedreich Ataxia Research Alliance (FARA), Inclusion and Exclusion criteria, primary and 
secondary outcome measures, rating scales, biomarkers, physical activity tests. 
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II. Pharmacotherapy of Friedreich ataxia (F.A.) 
According to the ongoing/completed clinical trials, 
currently there are around a dozen of drug molecules 
which are being evaluated for their efficacy against F.A. 
at different stages of clinical trials.However, few 
molecules are already been approved drugs for F.A. The 
results of treating ataxia in F.A. have generally been 
disappointing. No therapeutic measures are known to 
alter the natural history of the neurological disease. 
Standard treatment is administered for heart failure, 
arrhythmias, and diabetes mellitus. In one of case 
reports, high-dose propranolol has been described with 
reduction in thickness of the septal and posterior left 
ventricular walls and with complete normalization of 
diffuse electrocardiographic repolarization 
abnormalities.
iii
In another study it was postulated that 
therapeutic efforts should be focused on an approach 
that combines iron removal from mitochondria with a 
treatment that increases cytosolic iron levels to 
maximize residual frataxin expression in patients with 
F.A.
iv
 
The other therapies that have been widely investigated 
are as follows: 
1. 5-Hydroxytryptophan  
5-Hydroxytryptophan is a serotonin precursor that has 
been used for a decade or more to treat various forms of 
ataxia with mixed results.
v
This drug was known to 
suppress post-hypoxic action myoclonus. The rationale 
for use of the drug was that F.A. may be causedin part 
due to cerebellar deficiency of serotonin.The results of a 
double-blind, cross-over study demonstrated that the 
levorotatory form of 5-hydroxytryptophan was able to 
significantly modify the cerebellar symptoms in patients 
with F.A.; however, the effect was only partial and not 
clinically major.A study by Wessel Stabilization of 
posture in patients receiving long-term treatment with 
5-hydroxytryptophan was also demonstrated
vi
and a 
clear deterioration in patients who did not receive the 
treatment. This form of treatment required further study 
to validate proof of concept.  
2. Coenzyme Q  
Coenzyme Q is an antioxidant that buffers free radicals 
that are generated by excess of mitochondrial iron. A 
combined coenzyme Q (400 mg/d) and vitamin E (2100 
IU/d) therapy has been used which showed delayed 
progression of certain clinical features and a significant 
improvement in cardiac function
vii
. Experimental 
studies are underway to evaluate the use of coenzyme Q 
derivatives in limiting the toxicity of iron to 
mitochondrial structures.  
3. Idebenone 
Idebenone has been used as therapy for Friedreich 
ataxia for more than a decade. At present, several 
studies have assessed the influence of therapy on 
neurologic or cardiac function. The effect of 
intermediate-dose idebenone (20 mg/kg/d) on quality of 
life and neurologic function was assessed in a recent 
study by Brandsemaet al.
viii
In this study, the Pediatric 
Quality of Life Inventory, the International Cooperative 
Ataxia Rating Scale, and an Activities of Daily Living 
Scale before initiation of idebenone therapy and after 1 
year of therapy were assessed. The scores on the 
Pediatric Quality of Life Inventory were universally 
worse after 1 year and correlated with decreased 
activities of daily living scores. However, there was a 
trend toward improved total, emotional, social, and 
school components of quality of life scores after 1 year 
of idebenone therapy. There was no statistically 
significant change in Pediatric Quality of Life Inventory 
scores between baseline and 1 year of idebenone 
therapy. Functional ability, as measured by activities of 
daily living scores, seems to have the most influence on 
the physical quality of life. Prior randomized, double-
blind, placebo-controlled intervention trial by Lynch et 
al. did not reveal any statistically significant difference 
between the placebo and idebenone on the International 
Cooperative Ataxia Rating Scale.
ix
 
4. Interferon gamma 
Tomassiniet al. (2012) have revealed that in vivo 
treatment with interferon-gamma increases frataxin 
expression in dorsal root ganglia neurons, prevents their 
pathological changes, and ameliorates the sensorimotor 
performance in F.A. mice. These results disclose new 
roles for interferon-gamma in cellular metabolism and 
have direct implications for the treatment of 
F.A.
x
Pandolfoet al. have recently reviewed the utility of 
deferiprone with specific regard to its iron chelating 
properties and clinical benefits.
xi
 
III.   Primary and Secondary Outcome 
Measurements 
A summary of the clinical trials from clinicaltrials.gov 
and FARA is been compiled in Table 1.2. From the 
clinical trial summary, the primary and secondary 
outcome measures which are most commonly used in 
these efficacy studies are been discussed below in order 
of their significance for evaluating efficacy against F.A. 
A.) Rating Scales
xii
 
i. Friedreich Ataxia Rating Scale (FARS)2 
The Friedreich Ataxia Rating Scale (FARS) is made up 
of a measure of ataxia, activities of daily living subscale 
(ADL) and a neurological subscale. These scales also 
include the 8m walk at maximum speed (8MW), the 9-
hole peg test (9HPT), PATA rate and Low-Contrast 
Letter Acuity Test (LCAT).  
 Strengths:FARS scores correlate significantly with 
functional disability, activities of daily living 
scores and disease duration. FARS has a large 
effect size and requires fewer patients for an 
equivalently powered study.  
 Weaknesses:This scale captures a particular 
dimension of neurologic function in F.A., so as a 
composite measure, it is not good enough to predict 
disease status. 
ii. Scale For Assessment and Rating of Ataxia 
(SARA)
xiii,xiv, xv
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SARA is a clinical scale that is based on a 
semiquantitative assessment of cerebellar ataxia on an 
impairment level. SARA has eight items that are related 
to gait, stance, sitting, speech, finger-chase test, nose-
finger test, fast alternating movements and heel-shin 
test. Although the cerebellum is directly involved in the 
coordination of eye movements, oculomotor functions 
are not considered, as the validation trials indicated that 
they are determined by other factors than appendicular 
and midline ataxia. SARA underwent a rigorous 
validation procedure involving three large multi-center 
trials in SCA and non-SCA ataxia patients, as well as 
controls. 
iii.   International Cooperative Ataxia Rating Scale 
(ICARS)
xvi
 
The proposed scale involves a compartmentalized 
quantification of postural and stance disorders, limb 
ataxia, dysarthria and oculomotor disorders, in order 
that a sub-score concerning these symptoms may be 
separately studied. The members of the Committee 
agreed upon precise definitions of the tests, to minimize 
inter-observer variations. The validation of this scale is 
under progress. 
B.)  Physical Tests: 
Physical tests mainly correlate the stage of ataxia in 
Friedreich ataxic patients. Ataxia is a non-specific 
clinical manifestation implying dysfunction of the parts 
of the nervous system mainly cerebellumthat is 
involved in coordinatingmuscle movement.
xvii,xviii
 
Several possible causes exist for these patterns of 
neurological dysfunction. Different physical tests are 
employed to assess the progression of F.A. in Friedreich 
ataxia patients. These tests are as follows: 
1. 9-Hole Peg Test (HPT) 
2. Timed 25-Foot Walk (T25FW) 
3. Low Contrast Letter Acuity Test (LCLA) 
4. Visual Assessment Scale (VAS) 
1. 9-Hole Peg Test (HPT)
xix,xx,xxi
 
This simple test of manual dexterity records the time 
required for the participant to accurately place and 
remove nine plastic pegs into a plastic pegboard.  The 
protocol includes 1 practice and 1 timed trial with each 
hand.  Raw scores are recorded as time in seconds that 
it takes the participant to complete the task with each 
hand (a separate score for each) (Figs.I a) 
 
Figure I:    9-Hole Peg Test (HPT) 
2. Timed 25 Foot Walk Test (T-25 FW) 
In this test the subject should walk 7.62 meters (25 feet) 
as quickly, but safely, as possible without running. The 
path on which the test is walked, such as a hallway, 
should be clearly marked and free of obstructions. 
Patients are permitted to use their own assistive device 
or, in the case of a clinical trial or serial study, the best 
assistive device that might be necessary. The timed-
walk test should be performed twice, the time being 
recorded in seconds, starting as the lead foot passes the 
start line and ending as the lead foot passes the finish 
line. 
xxii, xxiii
 
 
Figure II:   Time 25 foot walk test 
C.)Biomarkers: 
Frataxin, 8-Hydroxy-2-deoxyguanosine, Peroxides and 
Plasma F2- isoprostanes are some of the biomarkers 
used for assessing the clinical state of Friedreich ataxia. 
These are discussed in more detail below. 
a) Frataxin: 
Friedreich ataxia (FRDA) is a neurodegenerative 
disease caused by mutations in the frataxin (FXN) gene, 
resulting in reduced expression of the mitochondrial 
protein frataxin.Frataxin is localized in the 
mitochondrion. The function of frataxin is not entirely 
clear, but it seems to be involved in assembly of iron-
sulfur clusters. It has been proposed to act as either an 
iron chaperone or an iron storage protein. Lateral flow 
“dipstick” immunoassay for the measurement of 
frataxin protein in multiple peripheral cell types is 
employed as a determination technique for FRATAXIN 
levels. The dipstick assay showed utility in a variety of 
clinical applications, including preliminary diagnosis of 
atypical FRDA patients, analysis of longitudinal 
frataxin measurements, correlations with changes in 
neurological severity.
xxiv
This technique does not require 
isolation or purification of mitochondria.
xxv
 
Lymphocytes are mainly used for assessing 
peripherialfrataxin levels. The importance of 
lymphocytic frataxin levels in the assessment of 
friedreich ataxia are noted as under: 
i. Lymphocytes are suitable for large scale clinical 
trials, 
ii. Lymphocytes show higher frataxin levels as 
compared to buccal cells in controls, known 
carriers and patients. Coefficient of variation is 
fewer amongst the control individuals.
xxvi
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iii. Highest levels of frataxin in blood are found in 
erythrocytes. As erythrocytes are not useful for 
frataxin assessment in many clinical trial 
situations, PBMCs (Peripherial blood 
mononuclear cells) and buccal swabs have 
frataxin levels equivalent to those of whole 
blood. In addition, a dose-dependent increase in 
frataxin was observed when PBMCs isolated 
from patient blood were treated with Histone 
Deacetylase Inhibitors (HDACi).
xxvii
 
iv. Frataxindownregulation is associated with 
robust changes in gene expression in PBMCs 
(lymphocytes), providing pathogenetic insights 
and a core subset of genes that, if verified in 
vivo, could be used as a peripheral 
biomarker.
xxviii
 
b) 8-Hydroxy-2-Deoxyguanosine: 
DNA is subject to constantoxidative damage from 
endogenous oxidants. The oxidized DNA is 
continuously repaired and the oxidized bases are 
excreted in the urine. A simple routine analytical 
procedure is described for urinary 8-hydroxy-2'-
deoxyguanosine, an oxidative DNA damage adduct, as 
an indicator of oxidative damage in humans and 
rodents.
xxix
 This adduct was purified from human urine 
and characterized. The described assay employs a series 
of solid phase extraction steps that separate 8-hydroxy-
2'-deoxyguanosine from other urinary constituents, 
followed by analysis by gradient reversed-phase HPLC 
coupled to a dual electrode high-efficiency 
electrochemical detection system. Analysis of urine 
from three species by this method indicated that mice 
excrete approximately 3.3-fold more 8-hydroxy-2'-
deoxyguanosine than humans (582 vs. 178 residues per 
cell per day), a result that supported the proposal that 
oxidative damage to DNA increases in proportion to 
that of species-specific basal metabolic rates.
xxx
 
c) Peroxides: 
Frataxin and iron-sulphur cluster proteins deficiency 
causes accumulation of molecular iron in the cytoplasm 
of neurons. The increase in the amount of molecular 
iron causes production of reactive oxidative species 
mainly superoxides and peroxides by Fenton chemical 
reactions. These reactive oxidant species cause 
induction in the activity of antioxidant enzymes mainly 
superoxide dismutase (SOD) and Glutathione reductase 
(GR). The presence of these antioxidant enzymes are 
quantified using enzyme linked immunosorbent assay 
(ELISA).
xxxi,xxxii
 
d) Plasma F2 Isoprostanes: 
F2-isoprostanes are prostaglandin F2-like compounds 
that are known to be formed in vivo by free radical 
oxidation of arachidonyl-containing lipids inside the 
cell and when they come into the plasma, their plasma 
levels have been suggested as indicators of in vivo 
oxidative stress. As F2-isoprostanes are potent 
vasoconstrictors and can modulate platelet aggregation, 
their formation has important implications in the 
genesis of cardiovascular disease.
xxxiii
 
IV. Inclusion and Exclusion criteria 
Further, based on the clinical trials as listed in Table 
1.2, the most common inclusion and exclusion criteria, 
specific for F.A. efficacy assessment trials, are 
summarized below. Other general inclusion and 
exclusion criteria, which are common in most of the 
clinical trials are not being discussed here. 
Inclusion Criteria: 
1. Diseased individual: Patient with Friedreich ataxia 
and has had a genetic test demonstrating > 400 
G.A.A trinucleotide repeats on shorter of the two 
frataxin alleles, [A detailed analysis of such 
diagnosis is given in the Genetic predisposition 
section of Friedreich ataxia-epigenetics]. 
2. Scale for Assessment and Rating of Ataxia (SARA) 
(stance) subscore of <=6, 
3. SARA (gait) subscore of <=6, 
Exclusion Criteria: 
1. Patients unable to stand up even with support 
(Wheelchair bound patients), 
2. Iron deficiency defined as ferritin levels below the 
reference range for age- and sex-matched controls, 
3. Unable to complete T25FW and with score > 5 
minutes in the 9HPT. (Subjects who can complete 
T25FW or with a score ≤ 5 minutes in the 9HPT 
will be allowed to enroll if the score has not 
doubled compared to screening.) 
4. Subjects with a history of seizures. 
Further, regarding the number of subjects/ patients in 
these clinical trials have also been compiled according 
to the clinical trial phases.Table 1.1 provides a range of 
the enrollment in such studies related to F.A. according 
to the stages in the clinical trial, however, this range is 
very broad and may vary with the scope of the trial, 
therefore, the enrollments in individual trials from 
Table 1.2 may please be referred for more specific 
information.  
Table 1.1: Range Of Patient Enrollment According 
To Clinical Trial Phases 
 
 
 
 
Sr. 
No. 
Phases Range of Patient 
Enrollments 
1. I (Interventional) 16-100 
2. II (Interventional) 12-87 
3. III (Interventional) 40-232 
4. IV (Interventional) 01 
5. OBSERVATIONAL 30-40 
6. INTERVENTIONAL 20-52 
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Table 1.2: Test Drug Molecules According To Ongoing and Completed Clinical Trials: 
Sr. 
No. 
Test Drugs Title, Enrollments and Clinical Trial Phase 
1. Resveratrol 
(Antioxidant, neuroprotective) 
(Michio Takaokaet.al) 
A Study of Resveratrol as Treatment for F.A. (30) 
(Phase I and II interventional) 
2. Idebenone 
(Antioxidant) 
(Takeda Chemicals Ltd, Japan) 
1. Idebenone to Treat F.A. (51) (Phase II-Interventional), 
2. Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the 
Treatment of  F.A. (IONIA) (70), (Phase III-Interventional) 
3. Patient Reported Outcomes in  F.A. Patients After withdrawal From 
Treatment With Idebenone (PROTI) (80),(Phase III-Interventional) 
4. A Study of Efficacy, Safety and Tolerability of Idebenone in the 
Treatment of  F.A. (FRDA) Patients (MICONOS) (232), 
(Phase III-Interventional) 
3. Epoetinalfa 
(Increases frataxin levels) 
(Boesch S. et.al) 
1. Efficacy Study of Epoetin Alfa in  F.A. (FRIEMAX) (56) (Phase II- 
Interventional) 
2. Efficacy of Epoetin Alfa in Patients with  F.A. (10)  (Phase II 
Interventional) 
4. EPI-743 
(Improves visual function) 
(Edison Pharmaceutical Inc.) 
1. EPI-743 in  F.A. Point Mutations (04) (Phase II-Interventional), 
2. Safety and Efficacy of EPI-743 in Patients with  F.A. (60) 
(Phase II-Interventional), 
3. EPI-743 for Mitochondrial Respiratory Chain Diseases (87) 
(Phase II-Interventional). 
5. Varenicline(Nicotinic acetylcholine 
receptor agonist-Reduces pain 
associated with the symptoms.) 
(Dr. Zesiewiczet.al) 
Pilot Study of Varenicline (Chantix®) in the Treatment  F.A. (28) Phase II 
Interventional 
6. EGb-761 
(Antioxidant) 
(Ipsen) 
Efficacy of EGb761 in Patients Suffering From  F.A. (22) (Phase-II 
Interventional), 
7. Alpha tocopherolquinone-A0001 
(Antioxidant) 
(Penwest Pharmaceuticals Co.) 
Safety and Efficacy Study of A0001 in Subjects With  F.A. (42)(Phase II-
Interventional), 
8. Nicotinamide(Upregulatesfrataxingene 
expression) 
(Chan and Torres et.al) 
Effect of Nicotinamide (Vitamin B3) in  F.A. (20) (Phase II-Interventional), 
9. Interferon gamma-1b 
(Increases Frataxin levels) 
(Roberto Testi and Barbara 
Tomassiniet.al) 
Interferon Gamma-1b in FRDA (12) (Phase II-Interventional), 
10. Ironchelating intervention. 
(Antioxidant) 
Iron-Chelating Therapy and  F.A. (15)  (Phase I/II- Interventional) 
11. Pioglitazone (ACTOS) 
(PPAR-gamma agonist) 
(Restores Normal Superoxide 
dismutase function.) 
(Massimo Pandolfoet.al) 
Effect of Pioglitazone Administered to Patients With  F.A.: Proof of Concept 
(ACTFRIE) (40) (Phase III-Interventional). 
12. Riluzole(Rilutek by Sanofi-Aventis) 
(Neuroprotective via inhibition of 
NMDA  receptor) 
Efficacy of Riluzole in Hereditary Cerebellar Ataxia (60) (Phase II-
Interventional). 
13. Bupropion+ 
citalopram, 
Bupropion+ 
Placebo, 
Placebo+ 
Citalopram, 
Placebo+ 
Placebo. 
(Antidepressant and 
Antipsychotic activity) 
An Objective Double-blind Evaluation of Bupropion and 
Citalopram in an Individual With  F.A. (1) 
(Phase IV-Interventional) 
14. Deferiprone 
(Antioxidant)(Arnold Munnichet.al, 
Apotex Technologies Inc.) 
Efficacy and Safety of the Iron ChelatorDeferiprone in Parkinson's disease 
(FAIR-PARK-I) (40) 
(Phase II-Interventional) 
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V.  Institutions Working for the Research and 
Treatment of Friedreich Ataxia: 
1. The Collaborative Clinical Research Network in 
Friedreich's Ataxia(CCRN in FA): 
It is an international network of clinical research working 
together for advance treatments and clinical care for 
individuals with Friedreich's ataxia. The network 
collaborates with pharmaceutical companies, government 
agencies and other research centers and the patient 
community to facilitate clinical research and trials 
needed to identify new therapies.
xxxiv
 
2. FARA (Friedreich Ataxia Research Alliance) 
 (FARA) is a national, public, 501(c)(3), non-profit, tax-
exempt organization dedicated towards curing 
Friedreich’s ataxia (FA) through research. FARA grants 
and activities provide support for basic and translational 
FA research, pharmaceutical/ biotech drug development, 
clinical trials, and scientific conferences.
xxxv
 FARA being 
a multifunctional organization which endorses following 
features: 
i. FARA Patient Registry: 
The FARA patient registry is the worldwide registry of 
Friedreich ataxia patients. Over 1800 Friedreich ataxia 
patients, from across the United States and 
internationally, have registered their demographic and 
basic clinical information in this database.
xxxvi
 
ii. FARA’s Grant Program: 
FARA supports research through funding competitive 
grants, promoting collaboration among scientists, 
advocating for public-private partnerships that support 
drug discovery, drug development and clinical research 
and hosting open forums for leading scientists to share 
their insights, ideas and challenges to advancing 
treatments for F.A. 
In addition to General Research Grants, FARA offers 
named awards for projects fitting specific criteria: (1) 
Cardiac Research; (2) Translational Research; and (3) 
International Collaborative Research.The proposed 
research must fall within FARA’s Grant Program 
Priorities. 
 
Table 1.3: Grant Types, Deadlines and Budget Limits under FARA
xxxvii
 
Grant Type 
Letter of Intent 
(LOI) Deadlines 
Application 
Deadlines 
Maximum Budget 
(in US dollars) 
General Research Grant 
Feb 1 
July 15 
April 1 
Sept 15 
$150,000 per year 
for 1 or 2 years 
Keith Michael Andrus Cardiac 
Research Award 
January 15 March 1 
$150,000 per year 
for 1 or 2 years 
Phillip Bennett and Kyle Bryant 
Translational Research Award 
May 15 July 15 
$250,000 per year 
for 1 or 2 years 
Bronya J. Keats International 
Research Collaboration Award 
May 15 July 15 
$200,000 per year 
for 1 or 2 years 
All applications will be peer-reviewed and scored as described in the Review and Decision Process.  
 
FARA, Ataxia UK and GoFARalso invite proposals for 
projects to develop biomarkers by non-invasive 
approaches for evaluating the molecular and 
pathological features of affected neurons in Friedreich’s 
ataxia patients.
xxxviii
Grant Program Review and 
Decision Process
xxxix
 and Grant Program Reporting 
Requirements
3
 are elucidated in detail in the cited 
reference. 
3. Additional Grant-Making Organizations: 
Non-Profit Organizations 
 National Ataxia Foundation 
 Muscular Dystrophy Association 
 Ataxia UK 
 FARA - Australasia 
 American Heart Association 
US Government Agencies 
                                                 
 
NIH 
Principle concern of the NIH is to invest tax dollars 
wisely and to beentrusted for the support and conduct of 
vital biomedical research. 
VI. Conclusion: 
Severe motor dysfunction in the pathophysiology of the 
disease is found to be highly devastating and scientists 
throughout the globe are aiming at reducing both the 
central genetic abnormality and the peripherial ataxic 
symptoms.Several test drug molecules are currently 
being evaluated at different stages of clinical trials for 
treatment ofcentral hyperoxidative state and peripherial 
symptoms of Friedreich ataxia. However, molecules 
which treat the genetic defect of FXN gene in 
Friedreich ataxia form the present forefront treatment 
modality for Friedreich ataxia. For assessing the 
efficacy of the test drug molecules, primary outcome 
measures are being constructed which includes various 
rating scales viz. FARS, SARA and ICARS, physical 
activity tests viz. 9-Peg hole test and Timed 25 foot 
walk test (T25FWT), Biomarkers for assessing the stage 
of disease viz. frataxin, 8-Hydroxy-2-deoxyguanosine, 
peroxidase, Plasma F2-Isoprostanes are also been 
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evaluated. Changes in these outcome measures after the 
test drug therapy, are been primarily assessed in 
ongoing and completed clinical trials. Secondary 
outcome measures including cardiomegaly, blood 
glucose tolerance and visual changesare also been 
assessed.Friedreich Ataxia Research Alliance (FARA) 
is a non-profit organization working for rehabilitation 
and treatment of Friedreich ataxia patients. FARA 
maintains a huge patient registry. These patients are 
then employed for the conduct of clinical trials of 
various test molecules at various phases of clinical 
trials. FARA in addition to other organizations, provide 
various grants for conducting research in the field of 
Friedreich ataxia pathophysiology and clinical 
improvement of the disease condition. Thus, knowing 
the genetic predisposition of Friedreich ataxia and 
development of various test molecules which are found 
to improve symptoms and the disease progression of 
Friedreich ataxia, the morbidity rate of the disease could 
be improved and the mortality rate of the patient could 
then be reduced. 
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